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Abstract
Background: Subcutaneous erenumab reduced monthly migraine days and increased the likelihood of achieving
a ≥ 50% reduction at all monthly assessment points tested in 2 pivotal trials in episodic migraine (EM) and chronic
migraine (CM). Early efficacy of migraine preventive medications is an important treatment characteristic to patients.
Delays in achievement of efficacy can result in failed adherence. The objective of these post-hoc analyses were to
evaluate efficacy in the first 4 weeks after initial subcutaneous administration of erenumab 70 mg, erenumab
140 mg, or placebo.
Methods: There is no generally accepted methodology to measure onset of action for migraine preventive medications.
We used a comprehensive approach with data from both studies to evaluate change from baseline in weekly migraine
days (WMD), achievement of ≥ 50% reduction in WMD, and proportion of patients experiencing migraine measured on a
daily basis. The 7-day moving averages were overlaid with observed data.
Results: In both studies (EM: N = 955; CM: N = 667), there was evidence of onset of efficacy of erenumab vs. placebo
during the first week of treatment, which in some cases reached nominal significance. For EM the changes in WMD were
(least squares mean [LSM] [95% CI]): placebo, − 0.1 (− 0.3, 0.0); erenumab 70 mg, − 0.3 (− 0.5, − 0.2) p = 0.130;
erenumab 140 mg, − 0.6 (− 0.7, − 0.4) p < 0.001. For CM the changes were: placebo, − 0.5 (− 0.8, − 0.3); erenumab
70 mg, − 0.9 (− 1.2, − 0.7) p = 0.047; erenumab 140 mg, − 0.8 (− 1.1, − 0.5) p= 0.18. Achievement of ≥ 50% reduction in
WMD was observed as early as Week 1 (adjusted OR [95% CI] erenumab vs placebo) in EM: erenumab 70 mg, 1.3 (1.0, 1.9)
p = 0.097; erenumab 140 mg, 2.0 (1.4, 2.7) p < 0.001. A similar outcome was observed for CM: erenumab 70 mg, 1.8
(1.1, 2.8) p = 0.011; erenumab 140 mg, 1.9 (1.2, 2.9) p = 0.009. Seven-day moving averages of observed data
showed each treatment arm differed from placebo by Week 1 (OR [95% CI]): in EM Day 3 for erenumab 140 mg,
0.7 (0.5, 1.0) p = 0.031 and at Day 7 for 70 mg, 0.6 (0.4, 0.8) p = 0.002; in CM: Day 6 for erenumab 70 mg, 0.6 (0.4, 0.9)
p = 0.022 and at Day 7 for 140 mg, 0.7 (0.4, 1.0); p = 0.038.
Conclusion: Erenumab showed early onset of efficacy with separation from placebo within the first week of treatment
in both chronic and episodic migraine patients.
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Migraine preventive clinical trial
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Background
Migraine can result in severe disability with substantial bur-
den for patients and families [1, 2]. Disruptions to work life,
activities of daily living, social and leisure activities, and
physical and emotional functioning may occur both during
and between migraine attacks [3, 4]. Migraine-related dis-
ability and burden is present in patients with episodic mi-
graine (EM) and those with chronic migraine (CM), and
studies show patients prefer effective and well-tolerated
preventive treatments with rapid onset of action [5].
In order to avoid adverse effects, most commonly pre-
scribed preventive medications (e.g. beta-blockers, tricyc-
lic antidepressants, topiramate, and valproate) require
titration, and once the proper dose is attained, efficacy can
still be delayed. This delay in efficacy, coupled with toler-
ability issues, contributes to poor adherence and, ultim-
ately, failed migraine prevention. Achieving rapid efficacy
of c migraine preventive therapy could reduce the need
for acute treatments or even, in some particularly severe
situations, transitional therapies (e.g. corticosteroids) that
are required when patients have to wait for a migraine
preventive therapy to have an effect [6].
Research on migraine neurobiology conducted over the
last two decades demonstrated that calcitonin gene-related
peptide (CGRP) plays an important role in migraine patho-
physiology, and that targeting this pathway can be an ef-
fective preventive treatment strategy for migraine [7–9].
Erenumab is a fully human monoclonal antibody (mAb)
that binds and inhibits the canonical CGRP receptor [10].
The efficacy and safety of erenumab 70 mg and 140 mg
monthly have been shown in a 24-week, double-blind,
placebo-controlled clinical trial in EM [11] (STRIVE) and a
pivotal 12-week double-blind, placebo-controlled clinical
trial in CM [12]. In these 2 studies, both doses of erenu-
mab were effective in reducing monthly migraine days
(MMD; primary efficacy measure in both studies) at
all monthly time points tested in patients receiving
regular treatment every 4 weeks, including the earliest
pre-specified time point of Week 4, which suggests
that both doses of erenumab could also be effective
at even earlier time points [11, 12].
There are no standard methodological approaches for
assessing time to initial onset of efficacy in preventive
therapies for migraine. Clinical trial endpoints typically
compare mean MMD during treatment to MMD during a
1-month baseline. As the earliest pre-specified efficacy
time point in erenumab prevention trials was Month 1
(Week 4), in order to further refine our understanding of
the time to onset of efficacy of erenumab, we conducted
post hoc analyses of these two pivotal studies in EM and
CM, during the double blind phase, at time points earlier
than Week 4. We focused on migraine day frequency here,
as it is the most relevant measure, and it is related to pri-
mary and key secondary endpoints in our studies.
Methods
The EM and CM studies
The EM study (NCT02456740, STRIVE) was an inter-
national, randomized, double-blind, placebo-controlled,
parallel-group, phase 3 pivotal regulatory trial of erenu-
mab 70 mg and 140 mg administered monthly by sub-
cutaneous (SC) injection in adult patients with EM
where randomization was stratified by region and by
preventive migraine medication use (Fig. 1a) [11]. The
CM study (NCT02066415) was an international, random-
ized, double-blind, placebo-controlled, parallel-group piv-
otal regulatory trial in adult patients with CM where
randomization was stratified by region and medication
overuse (Fig. 1b) [12]. Detailed information on study de-
signs, populations, and results are provided in the primary
publications [11, 12]. The two studies were selected for
post-hoc analyses on onset of efficacy given their design
(i.e. placebo-controlled), sample size and the use of both
doses of erenumab, 70 mg and 140 mg, across the two mi-
graine categories, EM and CM.
Each day during the studies, patients completed an
electronic diary with information about their migraine
and non-migraine headaches, patient reported outcomes
(e.g. physical impairment) and use of acute migraine
therapies during the 1-month baseline phase and subse-
quent double-blind treatment phase. The primary end-
point was the change from baseline in MMD averaged
over Months 4, 5, and 6 for the EM trial and at Month 3
in the CM trial, with additional pre-specified analyses at
the end of each monthly treatment period. The migraine
day definition in both studies followed International Clas-
sification of Headache Disorders 3rd Edition (ICHD-3)
definitions for migraine and probable migraine [13]. The
protocol and patient consent information were approved
by all relevant ethical review boards, all subjects gave writ-
ten informed consent, and the studies were conducted in
accordance with the principles of the Declaration of
Helsinki and Good Clinical Practice [14].
Statistical analyses
The full methods for statistical analyses of each study
were published previously [11, 12]. To assess the efficacy
of erenumab versus placebo earlier than Week 4, post
hoc analyses evaluated the change from baseline in the
number of migraine days per week (WMD) and achieve-
ment of ≥ 50% reduction from baseline in WMD in the
total study populations.
The baseline mean WMD was calculated on the basis
of the entire 4-week baseline period (normalized into a
7-day period). For change from baseline in WMD, the
least squares mean (LSM) at each time point was calcu-
lated with adjusted analyses using a generalized linear
mixed-effects model that included treatment group, visit
(week), treatment by visit interaction, stratification factors
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and average WMD at baseline as covariates. For achieve-
ment of ≥ 50% reduction in WMD, odds ratios (ORs) at
each weekly time point were estimated using the stratified
Cochran-Mantel-Haenszel test with missing data imputed
as nonresponse.
To observe trends in efficacy at time points even
earlier than the first scheduled visit at Week 4, the daily
incidence of migraine during the first 2 weeks was ana-
lyzed. The proportion of patients with presence of mi-
graine was plotted for each day during Days 1–14 (first
2 weeks of the double-blind treatment phases of the
studies). The slopes and moving averages (7-day average,
taking into account observations 3 days before and after
a given day) were calculated and overlaid with observed
data. In addition, the ORs of migraine presence for each
day were estimated for the first 2 weeks using a general-
ized linear mixed-effects model that included treatment
group, visit (day), treatment by visit interaction, stratifi-
cation factors and baseline values (presence of migraine
on the day prior to the first dose) as covariates.
P-values for these post-hoc endpoints are based on
ORs or LSM differences from placebo and are not ad-
justed for multiple comparisons. Statistical significance
was determined by comparing descriptive p-values with
nominal significance level at p ≤ 0.05.
Results
Change from baseline in weekly migraine days
The WMD at baseline were 2.1 ± 0.6 for EM, and 4.5 ±
1.2 for CM. In the EM study, erenumab treatment was
associated with nominally significant reductions in
WMD compared to placebo as early as Week 1 and for
all doses by Week 4; (LSM change from baseline [95%
CI]) in the EM study: placebo (− 0.1 [− 0.3, 0.0]), 70 mg
(− 0.3 [− 0.5, − 0.2]; p = 0.130) and 140 mg (− 0.6[− 0.7,
− 0.4]; p < 0.001) for Week 1; placebo (− 0.4 [− 0.5, − 0.2]),
70 mg (− 0.6 [− 0.8, − 0.5]; p = 0.029) and 140 mg (− 0.6
[− 0.8, − 0.5]; p = 0.019) at Week 4. For CM, erenumab
treatment was associated with nominally significant reduc-
tions in WMD compared to placebo for both doses at
Week 1 and efficacy was sustained through Week 4; (LSM
change from baseline [95% CI]) in the CM study: placebo
(− 0.5 [− 0.8, − 0.3]), 70 mg (− 0.9 [− 1.2, − 0.7]; p = 0.047)
and 140 mg (− 0.8 [− 1.1,− 0.5]; p = 0.18) for Week 1;
placebo (− 0.8 [− 1.0, − 0.6]), 70 mg (− 1.5 [− 1.7, − 1.2];
p < 0.001) and 140 mg (− 1.4 [− 1.6, − 1.1]; p = 0.002) at
Week 4 (Fig. 2).
≥ 50% reduction from baseline in weekly migraine days
In both studies, the odds of achieving a ≥ 50% reduction
from baseline in WMD were higher in patients who re-
ceived erenumab compared with those who received pla-
cebo as early as the first week and sustained through
Week 4 (adjusted OR [95% CI]) for erenumab versus
placebo in the EM study: 70 mg (1.3 [1.0, 1.9]; p =
0.097) and 140 mg (2.0 [1.4, 2.7]; p < 0.001) for Week
1, 70 mg (1.5 [1.1, 2.0]; p = 0.020) and 140 mg (1.4 [1.0,
2.0]; p = 0.033) at Week 4; adjusted OR (95% CI) vs
placebo in the CM study: 70 mg (1.8 [1.1, 2, 8]; p =
0.011) and 140 mg (1.9 [1.2, 2.9]; p = 0.009) for Week
1, 70 mg (2.2 [1.5, 3.3]; p < 0.001) and 140 mg (2.4 [1.6,
3.5]; p < 0.001) at Week 4 (Fig. 3).
Fig. 1 Study design of the episodic migraine trial (a) and the chronic migraine trial (b)
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Proportion of patients with a migraine day and 7-day
moving averages
Although there was some variability between the studies
regarding the day of efficacy onset for erenumab, efficacy
was observed within the first week following treatment
initiation in both studies and was sustained through
Week 4 (Fig. 4). In the EM study, the first occurrence of
significance comparing the odds of having a migraine
day versus placebo was at Day 3 for erenumab 140 mg
(OR [95% confidence interval (CI)]: 0.67 [0.47, 0.96];
p = 0.031) and at Day 7 for 70 mg (OR [95% CI]: 0.55
[0.38, 0.80]; p = 0.002). In the CM study, the first oc-
currence of significance comparing the odds of having
a migraine day versus placebo was at Day 6 for erenu-
mab 70 mg (OR [95% CI]: 0.62 [0.42, 0.93]; p = 0.022)
and at Day 7 for 140 mg (OR [95% CI]: 0.65 [0.43,
0.98]; p = 0.038). Moreover, 7-day moving averages of
observed data of each erenumab treatment arm were
separated from placebo within the first week (Fig. 4).
Discussion
In this manuscript we report post hoc results of three
different sets of analyses from two (EM and CM) studies:
WMD, ≥ 50% reduction in WMD, and proportion of sub-
jects with a migraine on a given day (time to the first day
with nominally significant reduction in odds for having a
migraine for erenumab compared to placebo). The totality
of these exploratory analyses supports a time to onset of
efficacy of erenumab within the first week in both EM and
CM. These effects were sustained through Week 4, prior
to the next monthly dose of erenumab, and continued
throughout the double-blind phases of both studies at all
time points [11, 12] . Additionally, at Week 1, 43% (EM)
and 26% (CM) of patients in the erenumab 140 mg group
experienced a ≥ 50% reduction in WMD (15% increase vs
placebo [EM] and 10% increase vs placebo [CM]) (Fig. 3).
Since there is no commonly accepted methodology for
measuring onset of efficacy in migraine prevention, several
analytical approaches were used in this study. These
Fig. 2 Change from baseline in WMD during the first month of studies in episodic migraine (a) and chronic migraine (b)
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analyses support the onset of the efficacy of erenumab ver-
sus placebo in the week after the first injection. For weekly
analyses of change in migraine frequency and ≥ 50% re-
sponse rates, point estimates were slightly lower for Week
1 than for Week 2; moreover, the efficacy estimates at the
end of Week 1 were attenuated by the inclusion of results
for the first 2–3 days (when plasma concentrations of ere-
numab were still rising). Figure 4 shows that efficacy at the
end of Week 1 was greater than efficacy at the beginning of
Week 1 and comparable to efficacy observed in Week 2.
The data presented here are consistent with the phar-
macokinetic profile of erenumab following SC injection
[15]. A population pharmacokinetic model (based on
data from EM and CM studies) was used to fit observed
data to full pharmacokinetic profiles. For SC dosing, the
absorption half-life was estimated at 2.3 days, yielding
time to maximal concentration of 4–11 days (with higher
maximal serum concentration [Cmax] for 140 mg). Consid-
ering the median pharmacokinetic profile, systemic erenu-
mab concentrations already exceed relevant clinical levels
(i.e. Week 12 Cmin under a 70 mg monthly regimen) by
Day 2 following a single 140 mg SC dose, or by Day 3 fol-
lowing a 70 mg SC dose.
Since the efficacy of migraine preventive medications
within the first few weeks of initiation has typically not been
analyzed and/or reported, it is difficult to compare the re-
sults of the analyses reported herein to existing migraine
medications; however, some data are available for fremane-
zumab, eptinezumab, and galcanezumab. Fremanezumab
(Teva Pharmaceuticals) has shown onset of efficacy results
in post hoc analyses from a study of 261 patients with CM
[16]. In this study, a different analytical approach was used
based on headache hours. There was a significant decrease
in the number of headache hours starting 3 days after the
highest dose (900 mg) was given (a dose not used in phase
3 trials), and 7 days after the lower dose (675/225 mg) was
given. For moderate or severe headache days, a significant
decrease was seen during the second week for both doses.
Initial onset of efficacy studies with eptinezumab
(Alder BioPharmaceuticals Inc) have been reported as an
abstract at a scientific meeting [17]. The study evaluated
the effects of eptinezumab or placebo on the likelihood
of having a migraine on any given day over each of the
first 4 weeks in 1072 subjects with CM. On day 1 post
intravenous infusion, the proportions of individuals hav-
ing a migraine were lower in those receiving eptinezu-
mab 100 mg (28.6%) or eptinezumab 300 mg (27.8%)
compared to those receiving placebo (42.3%) [17].
Data on the initial onset of efficacy with galcanezumab
(Eli Lilly) were presented in abstract form at a scientific
meeting [18]. In this post hoc analysis of data from a
phase 2a study of individuals with EM, migraine head-
ache days per week were reduced more in those receiving
LY2951742 (n = 106) compared to placebo (n = 110) as
early as Week one.
One strength of the analyses presented in this study is
that several complementary statistical approaches were
used to explore the onset of efficacy of erenumab from
Fig. 3 Proportion of patients with ≥ 50% reduction from baseline in WMD during the first month of studies in episodic migraine (a) and chronic
migraine (b)
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the first days of treatment in both EM and CM patients.
A comprehensive approach including the entire study
population was used. A limitation of this study is its
post hoc nature. Although the trials were powered for
the primary endpoint and were controlled for multipli-
city for all secondary endpoints, they were not pow-
ered for the type of analyses presented here. Further,
post hoc analyses are typically not adjusted for mul-
tiple comparisons as they are exploratory, rather than
confirmatory in nature [19–21]. In this context, pre-
sented p-values are nominal and should be considered
cautiously.
Conclusions
In patients with either EM or CM, treatment with ere-
numab showed onset of efficacy within the first week
after the first dose, based on a series of complementary
analytical approaches and (clinically) relevant efficacy
measures (i.e. WMD and ≥ 50% reduction of WMD).
After the first week, efficacy was sustained and separ-
ation from placebo continued thereafter for the rest of
the study as reported separately [11, 12]. In addition to
the favourable benefit-risk profile of erenumab, its early
onset of efficacy may prove an important benefit to pa-
tients with a high burden of disease.
Fig. 4 Percentage of patients with episodic migraine (a) chronic migraine (b) with a migraine day and 7-day moving averages for the 4-week
baseline period and first 4-weeks of double-blind treatment (top panel) and for the last week of baseline and first 2 weeks of double-blind
treatment (bottom panel)
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